Cost-Benefit Model Comparing Two Alternative Immunisation Programmes Against Serogroup C Meningococcal Disease: For Quebec Residents Aged 2 Months to 20 Years

Author： Rancourt C.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.21, Iss.6, 2003-01, pp. : 429-442

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Complications of Serogroup B Meningococcal Disease in Survivors: A Review

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 14, Iss. 3, 2014-10 ,pp. : 205-212

Bentham Science Publishers

Access to resources Recommend Favorite

Early meningococcal immunisation programme cost saving in Canada

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 410, 2003-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Booster dose of serogroup C meningococcal vaccine of value

By  

Inpharma, Vol. 1, Iss. 1599, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Review of the Cost Effectiveness of Immunisation Strategies for the Control of Epidemic Meningococcal Meningitis

By Miller Mark A.   Shahab Cathryn K.  

PharmacoEconomics, Vol. 23, Iss. 4, 2005-01 ,pp. : 333-343

Adis International

Access to resources Recommend Favorite

Meningococcal serogroup C vaccination programme well worth it in the UK

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 358, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite